Scholarlink

Background and objective <p>Soft tissue sarcomas are rare heterogeneous tumors that require extensive treatment and should only be treated in specialized sarcoma centers. Surgical R0 resection with negative margins is one of the most important positive predictors of disease-specific survival. Comprehensive healthcare economic analyses of inpatient treatment costs are largely lacking but are essential to ensure sustainable and cost-effective care.</p> Methods <p>This retrospective single center study analyzed the inpatient costs of 112 sarcoma cases treated at this university tumor center between 2020 and 2022. The statistical analyses were performed to identify variables that influence case underfunding. Additionally, the revenue distribution was examined with respect to the frequency and extent of underfunding using the cost matrix of the Institute for the Remuneration System in Hospitals (InEK).</p> Results <p>A&#xa0;negative revenue balance was observed in 66.1% of cases, leading to a&#xa0;total deficit exceeding € 222,000. Significant predictors of underfunding included prolonged operation times, duration of intensive care stay and exceeding the average length of stay. The highest negative revenues were identified in the categories of “infrastructure costs”, “medical technical services” and “operating room costs”.</p> Conclusion <p>The results reveal significant underfunding of surgical sarcoma treatment in a specialized university sarcoma center. Adjustments to diagnosis-related groups (DRG)-based reimbursement are urgently needed to ensure the economic sustainability of care while safeguarding patient safety, academic training and making clinical decisions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Unterfinanzierung chirurgischer Leistungen in der Sarkomtherapie: eine retrospektive Analyse stationärer Behandlungskosten an einem universitären Sarkomzentrum

  • 期刊论文

  • 发表日期：

    2025年6月6日

查看全文
  • Vladyslav Kavaka,
  • Rose Haag,
  • Louisa Sarica,
  • Johannes C. Heinzel,
  • Sebastian Hoffmann,
  • Lukas Bankamp,
  • Ingmar Rieger,
  • Claudius Illg,
  • Sabrina Krauß,
  • Katarzyna Rachunek-Medved,
  • Michael Cerny,
  • Dominik Steiner,
  • Henrik Lauer,
  • Jonas Kolbenschlag,
  • Adrien Daigeler,
  • Johannes Tobias Thiel

摘要

Background and objective

Soft tissue sarcomas are rare heterogeneous tumors that require extensive treatment and should only be treated in specialized sarcoma centers. Surgical R0 resection with negative margins is one of the most important positive predictors of disease-specific survival. Comprehensive healthcare economic analyses of inpatient treatment costs are largely lacking but are essential to ensure sustainable and cost-effective care.

Methods

This retrospective single center study analyzed the inpatient costs of 112 sarcoma cases treated at this university tumor center between 2020 and 2022. The statistical analyses were performed to identify variables that influence case underfunding. Additionally, the revenue distribution was examined with respect to the frequency and extent of underfunding using the cost matrix of the Institute for the Remuneration System in Hospitals (InEK).

Results

A negative revenue balance was observed in 66.1% of cases, leading to a total deficit exceeding € 222,000. Significant predictors of underfunding included prolonged operation times, duration of intensive care stay and exceeding the average length of stay. The highest negative revenues were identified in the categories of “infrastructure costs”, “medical technical services” and “operating room costs”.

Conclusion

The results reveal significant underfunding of surgical sarcoma treatment in a specialized university sarcoma center. Adjustments to diagnosis-related groups (DRG)-based reimbursement are urgently needed to ensure the economic sustainability of care while safeguarding patient safety, academic training and making clinical decisions.